Login / Signup

Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience.

Firas BaidounDong ChenMirinal S PatnaikNaseema GangatKebede BegnaMichelle ElliottWilliam Joseph HoganMark R LitzowAref A Al-Kali
Published in: Leukemia & lymphoma (2019)
Myelodysplastic syndrome unclassifiable (MDS-U) is a small subtype of myelodysplastic syndromes (MDS). However, rare literature exists in terms of natural progression and clinical outcome of patients with MDS-U. In the present study, we investigated the characteristics and the clinical outcomes of patients categorized as MDS-U based on 2008 World Health Organization criteria (WHO) in a single center comparing to other MDS groups. Out of eight hundred and two patients who met WHO criteria for MDS at our institution, ninety patients (11%) were initially classified as MDS-U. Upon pathological review, only half of the cases were confirmed to be MDS-U. With follow up, half of the MDS-U cases were reclassified to another subtype. We found neither significant difference in median overall survival nor in risk of transformation to acute myeloid leukemia when comparing MDS-U to other MDS groups. Additional larger studies are needed to confirm our results.
Keyphrases
  • end stage renal disease
  • chronic kidney disease
  • newly diagnosed
  • acute myeloid leukemia
  • peritoneal dialysis
  • prognostic factors
  • acute lymphoblastic leukemia
  • patient reported outcomes
  • single molecule